IRIDEX Corporation (Nasdaq: IRIX) today announced that it will debut Cyclo G6, the Company's first laser platform dedicated to the treatment of glaucoma, at this year's annual congress of the American ...
IRIDEX Corporation (Nasdaq: IRIX), a leading global provider of innovative laser systems, delivery devices and consumables in ophthalmology, today announced that it has received its CE Mark to ...
IRIDEX received its CE Mark to commercialize across Europe its first laser system in its class designed solely for use in treating glaucoma and its symptoms, according to News-Medical. 1. The Cyclo G6 ...
Please provide your email address to receive an email when new articles are posted on . We recently presented results from a retrospective analysis of 26 eyes of 20 patients who underwent MP3 ...
MOUNTAIN VIEW, Calif., July 10, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today announced that in the second quarter of 2018 it has shipped the 1,000th unit of its Cyclo G6™ Laser ...
Chopped CW source allows tissue to cool between pulses. MOUNTAIN VIEW, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX), a leading provider of innovative laser systems in ...
Laser Platform Supports Family of Consumable Probes and Appliances Including Recently Patented MicroPulse® P3 Disposable. MOUNTAIN VIEW, Calif., Feb. 23, 2015 /PRNewswire/ -- IRIDEX Corporation (IRIX) ...
IRIDEX provides laser systems, devices and consumables in ophthalmology. Today it has announced its CE Mark to commercialize its Cyclo G6 laser system to treat glaucoma across Europe. The Cyclo G6 ...
MicroPulse ® Transscleral Laser Therapy (TLT), continuous-wave transscleral cyclophotocoagulation (CW-TSCPC), and MicroPulse Laser Trabeculoplasty (MLT) are non-incisional treatments that expand ways ...
Generated total revenue of $12.9 million, a decrease of 7% year-over-year Cyclo G6® product family revenue of $3.7 million increased 5% year-over-year 41 Cyclo G6 Glaucoma Laser Systems sold, compared ...
Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2022
“We are pleased with our improved results in the second half of the year driven by record fourth quarter Cyclo G6 probe sales, the expanding base of Cyclo G6 Glaucoma Laser Systems and strong ...
Iridex Corporation reported preliminary Q4 2024 revenue of $12.6-$12.7 million, maintaining probe sales while focusing on profitability. Iridex Corporation announced its preliminary unaudited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback